SEARCH

SEARCH BY CITATION

References

  • 1
    Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:34765.
  • 2
    Vanfleteren LE, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:72835.
  • 3
    Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:3743.
  • 4
    Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009;4:33749.
  • 5
    Guthrie B, Payne K, Alderson P, McMurdo ME, Mercer SW. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012;345:e6341.
  • 6
    Boschetto P, Beghe B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology 2012;17:42231.
  • 7
    US Burden of Disease Collaborators. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591608.
  • 8
    Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:44857.
  • 9
    Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:74150.
  • 10
    Waatevik M, Skorge TD, Omenaas E, Bakke PS, Gulsvik A, Johannessen A. Increased prevalence of chronic obstructive pulmonary disease in a general population. Respir Med 2013;107:103745.
  • 11
    WHO, Media, centre. Fact sheet No 317. Secondary Fact sheet No 317 2013.
  • 12
    Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 2013;127:e6245.
  • 13
    Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation 2012;125:114756.
  • 14
    Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26.
  • 15
    Mullerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in chronic obstructive pulmonary disease: systematic literature review. Chest 2013;144:116378.
  • 16
    Eriksson B, Lindberg A, Mullerova H, Ronmark E, Lundback B. Association of heart diseases with COPD and restrictive lung function–results from a population survey. Respir Med 2013;107:98106.
  • 17
    Reed RM, Eberlein M, Girgis RE, Hashmi S, Iacono A, Jones S et al. Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am J Med 2012;125:1228 e1328 e22.
  • 18
    Formiga F, Ferrer A, Sanz H, Marengoni A, Alburquerque J, Pujol R. Patterns of comorbidity and multimorbidity in the oldest old: the Octabaix study. Eur J Intern Med 2013;24:404.
  • 19
    García-Olmos L, Alberquilla A, Ayala V, García-Sagredo P, Morales L, Carmona M et al. Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study. BMC Fam Pract 2013;14:11.
  • 20
    de Lucas-Ramos P, Izquierdo-Alonso JL, Rodríguez-González Moro JM, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M et al. [Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study]. Arch Bronconeumol 2008;44:2338.
  • 21
    Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:15561.
  • 22
    Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012;106:24956.
  • 23
    Sibila O, Mortensen EM, Anzueto A, Laserna E, Restrepo MI. Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. Eur Respir J 2013. doi: 10.1183/09031936.00117312. [Epub ahead of print].
  • 24
    Brekke PH, Omland T, Smith P, Soyseth V. Underdiagnosis of myocardial infarction in COPD - Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008;102:12437.
  • 25
    Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011;32:236575.
  • 26
    Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:6370.
  • 27
    Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009;122:34855.
  • 28
    Nishiyama K, Morimoto T, Furukawa Y, Nakagawa Y, Ehara N, Taniguchi R et al. Chronic obstructive pulmonary disease–an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. Int J Cardiol 2010;143:17883.
  • 29
    Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L et al. Impact of COPD on long-term outcome after St-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013;144:7507.
  • 30
    McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012;39:1097103.
  • 31
    Man SF, Van Eeden S, Sin DD. Vascular risk in chronic obstructive pulmonary disease: role of inflammation and other mediators. Can J Cardiol 2012;28:65361.
  • 32
    Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007;370:7979.
  • 33
    Kawut SM. COPD: CardiOPulmonary disease? Eur Respir J 2013;41:12413.
  • 34
    Maclay JD, Macnee W. Cardiovascular disease in COPD: mechanisms. Chest 2013;143:798807.
  • 35
    Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009;360:244554.
  • 36
    Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects of smoking. Chest 2007;131:155766.
  • 37
    Radak D, Babic S, Peric M, Popov P, Tanaskovic S, Babic D et al. Distribution of risk factors in patients with premature coronary, supra-aortic branches and peripheral atherosclerotic disease. Med Princ Pract 2012;21:22833.
  • 38
    Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635701.
  • 39
    Watz H, Waschki B, Kirsten A, Müller KC, Kretschmar G, Meyer T et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009;136:103946.
  • 40
    Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:20412.
  • 41
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:168595.
  • 42
    Kaptoge S, DiAngelantonio E, Pennells L, Wood AM, White IR, Gao P et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:131020.
  • 43
    Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:134151.
  • 44
    Soriano JB, Rodriguez-Roisin R. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc 2011;8:3637.
  • 45
    Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:212938.
  • 46
    Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 2012;7:e37483.
  • 47
    Bertoletti L, Quenet S, Mismetti P, Hernández L, Martín-Villasclaras JJ, Tolosa C et al. Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012;39:8628.
  • 48
    Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010;74:225762.
  • 49
    Roca M, Verduri A, Corbetta L, Clini E, Fabbri LM, Beghe B. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 2013;43:51021.
  • 50
    Soriano JB, Rigo F, Guerrero D, Yañez A, Forteza JF, Frontera G et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010;137:33340.
  • 51
    Almagro P, López García F, Cabrera F, Montero L, Morchón D, Díez J et al. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. Respir Med 2010;104:2539.
  • 52
    Camp PG, O'Donnell DE, Postma DS. Chronic obstructive pulmonary disease in men and women: myths and reality. Proc Am Thorac Soc 2009;6:5358.
  • 53
    Aryal S, Diaz-Guzman E, Mannino DM. COPD and gender differences: an update. Transl Res 2013;162:20818.
  • 54
    Health, United States. 2012: With Special Feature on Emergency Care. Hyattsville, MD: Health, United States; 2013.
  • 55
    Tam A, Sin DD. Why are women more vulnerable to chronic obstructive pulmonary disease? Expert Rev Respir Med 2013;7:1979.
  • 56
    Townsend EA, Miller VM, Prakash YS. Sex differences and sex steroids in lung health and disease. Endocr Rev 2012;33:147.
  • 57
    Papakonstantinou NA, Stamou MI, Baikoussis NG, Goudevenos J, Apostolakis E. Sex differentiation with regard to coronary artery disease. J Cardiol 2013;62:411.
  • 58
    Ekstrom MP, Jogreus C, Strom KE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS ONE 2012;7:e35806.
  • 59
    Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122.
  • 60
    Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569619.
  • 61
    Matera MG, Calzetta L, Rinaldi B, Cazzola M. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol 2012;12:31522.
  • 62
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:71925.
  • 63
    Decramer ML, Hanania NA, Lotvall JO, Yawn BP. The safety of long-acting beta2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013;8:5364.
  • 64
    Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012;12:48.
  • 65
    Ekstrom MP, Hermansson AB, Strom KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:71520.
  • 66
    Lahousse L, Loth DW, Joos GF, Hofman A, Leufkens HG, Brusselle GG et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013;26:2127.
  • 67
    Gross NJ. Novel antiinflammatory therapies for COPD. Chest 2012;142:13007.
  • 68
    Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41:101722.
  • 69
    Connet JA, Scharf SM, Dransfield M, Washko G, Albert LK, Casaburi R et al. Simvastatin Therapy for Moderate and Severe COPD (STATCOPE). NCT01061671 Available at: http://www.clinicaltrials.gov. Accessed on 22 June 2013.
  • 70
    Nozzoli C, Beghè B, Boschetto P, Fabbri LM. Identifying and treating COPD in cardiac patients. Chest 2013;144:7236.